

Stream Healthcare Recap

Expert insights that bring meaning to trending healthcare topics and upcoming events

April 2023

by Sara Mallatt Stahl, Stream Healthcare Sector Head

Stream in AlphaSense has an ever-growing expert call library offering a range of industry perspectives. For healthcare fans, look no further for an April 2023 recap of expert call transcripts that provoke deeper insights on trending healthcare topics, upcoming events, and market movers.

Top-Rated Transcripts

A selection of Stream expert call transcripts that are particularly insightful, thought-provoking or unique.

Biotech/Pharma	SRPT	<u>Former Head Believes There Is a 50-50 Chance That SRPT's SRP-9001 Will Receive FDA Accelerated Approval</u> - Former Head at Sarepta Therapeutics, responsible for product launches in the U.S. market
	RETA	<u>Neurologist Surprised by FDA Approval of RETA's Skyclarys for Friedreich's Ataxia but May Find a Role for it in Milder Patients</u> - Neurologist at Mayo Clinic
Healthcare Services	AMN	<u>Customer Does Not See a Return to 2018 Healthcare Staffing Levels Within the Next Two Years</u> - Director at Brigham and Women's Hospital
Managed Care	CNC	<u>Former Operations SVP Thinks CNC Is Starting to Take Steps in the Right Direction</u> - Former Senior Vice President, Operations, Population Health & Clinical Operations at Centene Corporation
MedTech	EW	<u>Interventional Cardiologist Thinks Headwinds Could Impact TAVR Growth Until Further Indication Expansion</u> - Interventional Cardiologist at BayCare Health System

Trending Topics

Stream expert call transcripts that provide context to important industry topics.

Medicare Advantage (MA) Rates

Experts at Stream share investor concerns over the effect of 2024 MA rate cuts (announced March 31) on margins of MA providers such as **CI, CVS, ELV, HUM** and **UNH**. However, experts at Stream are generally less pessimistic than the Street about the effect rate cuts are likely to have on MA enrollment, in line with Stream's [March Healthcare Recap](#).

"[Rate cuts] will create some cost pressure and maybe impact profitability, [but]...the trend toward Medicare population [growth] and [the] use of Medicare Advantage over straight Medicare is not going to stop. I don't think any national player can afford to get out of the [MA] game." - [Former Chief Medical Officer at Tandigm Health](#)

Medicaid Redeterminations

Stream's expert transcript library also provides detailed insights into how state Medicaid redeterminations, which began April 1, are likely to affect Medicaid managed care providers such as **CNC, CVS, ELV, MOH** and **UNH**.

"I believe most [health plans] are planning for a 15% member reduction in Medicaid... I'm fairly confident in [that estimate] because... most people on Medicaid are kids, so they're not going to lose their coverage... another 20% are expecting moms." - [Former Director, Analytics & Alignment at Highmark Inc.](#)

Gene Therapy

At an event earlier this month hosted by the Alliance for a Stronger FDA, a lobbying group for the agency, an FDA official laid out a plan to increase gene therapy approvals. Stream's expert transcript library has a trove of insights on opportunities and challenges in the gene therapy industry. Here's a sampling:

- [Industry Expert Believes Large Pharmaceutical Companies Are Moving Away From in-House CAR-T Cell Therapy Research](#) - Program Leader of Translational Cell Therapy Research, Assistant Professor of Heme/Med Oncology at Winship Cancer Institute of Emory University
- [Pediatric Hematologist Believes VRTX's Exa-cel and Other Gene Therapies Will Gradually Become Standard of Care for Sickle Cell Disease and Transfusion Dependent Thalassemia](#) - Pediatric Oncologist at Albert Einstein Medical Center

- [Former Competitor Thinks the Most Important Advances in Cell and Gene Therapy Will Come From Delivery](#) - Former Executive Director of Gene Therapy and Consultant with Poseida Therapeutics, Inc.

Calliditas
Therapeutics'
Tarpeyo

CALT's stock is up strongly after releasing positive trial data last month for its Tarpeyo IgA nephropathy treatment. Since then, three nephrologists interviewed by Stream have all expressed enthusiasm for the drug. However, their Tarpeyo prescriptions have been held back by inadequate **CALT** sales representation, patient assistance programs and negotiations with insurance companies.

"We want to write the prescription, but we need some help... Calliditas has not done their job in distributing information to the medical directors of these insurance companies." - [Nephrologist at Dallas Nephrology Associates](#)

Robotic Surgery:
Medtronic vs.
Intuitive Surgical

MDT showcased its Hugo surgical robot at the Society of American Gastrointestinal and Endoscopic Surgeons' 2023 Annual Meeting held March 29 - April 1 in Montreal, amplifying the debate about Hugo's ability to take share from **ISRG's** market-leading da Vinci platform. Hugo is likely to have difficulty taking meaningful share from da Vinci, according to Stream experts such as [this thoracic surgeon](#) who has experienced both systems:

"We don't see any advantages to [Hugo]... If I have to learn something completely new, there has to be some advantage to it [because]... all of us have been trained in da Vinci." - [Chief of Thoracic Surgery at Lenox Hill Hospital](#)

Private Company
Focus

Three orthopedic surgeons who attended the American Academy of Orthopedic Surgeons (AAOS) conference last month, highlighted private orthopedic device maker **Arthrex** as having momentum in a growing market and a fourth said the same about **Relievable Medical Systems**. (See Stream's [AAOS Conference Note](#).)

"[Arthrex has] got a whole bunch of new stuff... that's causing folks like myself to say, 'Huh, I was using Zimmer last year, but this looks like a better device, so I'm going to switch over.'" - [Orthopedic Surgeon and Monterey Joint Replacement and Sports Medicine](#)

"One of the things that is of considerable interest... is [Relievable's] basivertebral nerve ablation for degenerative disc pain... That's a tremendous advance that was unavailable therapeutically just a few years ago. It has some significantly compelling clinical studies to validate it." - [Former Orthopedic Spine Surgeon at Palomar Health](#)

Coming Up

Stream expert call transcripts to help prepare for upcoming events.

[PROCEPT BioRobotics' Aquablation Procedure](#)

PRCT
6/1

On June 1, UNH will begin covering **PRCT**'s Aquablation procedure for benign prostatic hyperplasia (BPH). [This Stream interview](#) with a former **PRCT** sales representative shares an upbeat outlook for Aquablation in the U.S. market, while this [former PRCT sales rep in the EU](#) provides insight into challenges that Aquablation faces there.

[Anticipated FDA Approval Decision: Seres Therapeutics](#)

MCRB
4/26

On April 26, the FDA is expected to make an approval decision on **MCRB**'s SER-109 for recurrent C. difficile infection (rCDI). Feedback from gastroenterologists about SER-109 was quite positive in [this Stream interview](#), as well as [this interview](#) and [this one](#).

[FDA Meeting: Over-the-Counter Birth Control](#)

PRGO
5/9 - 5/10

On May 9-10, the FDA will meet to discuss making **PRGO**'s Opill contraceptive available without a prescription. [This OB/GYN](#), as well as [this one](#) and [this one](#), shared their opinions with Stream about Opill adoption should it be approved as an over-the-counter option.

About AlphaSense

Stream in AlphaSense is a searchable database of investor-led expert interviews based on one-on-one calls with former executives, customers, competitors, and channel participants across a breadth of industries. With our proprietary AI search technology, we help the leading financial institutions and corporations get up to speed about a company or topic in seconds.

[Start my free trial today!](#)